Valuation: Immatics N.V.

Market Cap 999M 893M 827M 748M 1.4B 95.06B 1.42B 9.95B 3.93B 49.72B 3.75B 3.67B 157B P/E 2026 *
-3.44x
P/E 2027 * -3.5x
Enterprise Value 723M 646M 598M 541M 1.01B 68.75B 1.03B 7.19B 2.85B 35.96B 2.71B 2.65B 114B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 16.9x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.19%
1 week+6.24%
Current month-18.56%
1 month-14.58%
3 months-21.26%
6 months-37.00%
Current year-31.90%
1 week 6.94
Extreme 6.935
7.95
1 month 6.65
Extreme 6.65
9.16
Current year 6.65
Extreme 6.65
11.94
1 year 6.65
Extreme 6.65
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 31/12/2018
Director of Finance/CFO 57 30/09/2025
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 51 30/06/2020
Chairman 70 30/09/2012
Director/Board Member 72 30/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/03/26 Other

Chief Financial Officer

350,000 0.2611%
18/03/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-2.19%+6.24%-29.76%-12.27% 999M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+7.23%+11.14%+74.78% 54.78B
+0.47%+5.10%+8.22%+101.52% 53.49B
-2.06%+2.51%+24.07%+50.98% 45.98B
-1.79%+0.49%+19.32%+122.77% 42.94B
-1.65%+3.34%+237.56%+819.04% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+18.47%+55.14%+45.58% 23.67B
Average +0.35%+2.86%+40.83%+132.30% 38.41B
Weighted average by Cap. +0.11%+2.60%+45.73%+149.45%

Financials

2026 *2027 *
Net sales 45.58M 40.75M 37.7M 34.14M 63.89M 4.34B 64.94M 454M 179M 2.27B 171M 167M 7.18B 39.53M 35.35M 32.71M 29.61M 55.42M 3.76B 56.33M 394M 156M 1.97B 148M 145M 6.23B
Net income -285M -255M -236M -214M -400M -27.15B -407M -2.84B -1.12B -14.2B -1.07B -1.05B -44.97B -312M -279M -258M -233M -437M -29.64B -444M -3.1B -1.23B -15.5B -1.17B -1.14B -49.08B
Net Debt -277M -247M -229M -207M -388M -26.31B -394M -2.75B -1.09B -13.76B -1.04B -1.02B -43.57B -330M -295M -273M -247M -462M -31.37B -470M -3.28B -1.3B -16.41B -1.24B -1.21B -51.94B
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
26/10/26 US$7.150 -2.19% 756,091
23/10/26 US$7.310 -3.05% 695,978
22/10/26 US$7.540 -1.95% 621,016
21/10/26 US$7.690 +2.40% 1,980,384
20/10/26 US$7.510 +6.52% 1,487,260
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.310USD
Average target price
16.97USD
Spread / Average Target
+132.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immatics N.V.
  1. Stock Market
  2. Stocks
  3. IMTX Stock